TriangleNCT00866281 · CITED IN SOURCE DOCUMENTS
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2015-12-22
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients \<18 years of age who have relapsed or refractory acute leukemias that may benefit from administration of midostaurin, including MLL-rearranged ALL and FLT3 positive AML.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT
Percentage of Participants With Best Overall Response by Indication
Time to Response With Midostaurin
Overall Survival With Midostaurin
Plasma Concentrations of Midostaurin and Its Metabolites CGP52421 and CGP62221
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs or SAEs and Death During the Study
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Mixed-lineage leukemia (MLL) gene rearranged Acute Lymphoblastic Leukemia (ALL), that does not respond to treatment or has relapsed from prior treatment; or FLT3 mutated Acute Myeloid Leukemia (AML) that does not respond to a second treatment or has relapsed from 2 prior treatments * Normal organ function, and chest x-ray * Expected survival greater than 8 weeks * Can care for most of personal needs and perform at least minimum activity Exclusion Criteria: * Patients with symptomatic leukemic central nervous system involvement or isolated extramedullary leukemia * Patients must not have received other treatments for leukemia within a predefined time period, 72 hours for medications, 2 months for transplants * Patients with heart function that is not normal * Patients with HIV or hepatitis * Patients with another severe disease or medical condition besides leukemia Other protocol-defined inclusion/exclusion criteria may apply
- healthy Volunteers
- false
- maximum Age
- 18 Years
- minimum Age
- 3 Months
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m\^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m\^2 bid cohort was 60 mg/m\^2.
- intervention Names
- Drug: midostaurin
- label
- 30 mg/m^2 bid
- type
- EXPERIMENTAL
- description
- Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m\^2 bid through oral route. The total daily dose in 60 mg/m\^2 bid cohort was 120 mg/m\^2.
- intervention Names
- Drug: midostaurin
- label
- 60 mg/m^2 bid
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- 30 mg/m^2 bid
- 60 mg/m^2 bid
- description
- Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
- name
- midostaurin
- other Names
- PKC412
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 22
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose limiting toxicity (DLT), based on a Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. A DLT was defined as a grade 3 or 4 non-hematological adverse event (AE) or abnormal laboratory value related to study drug. Mean and the 95% posterior probability estimates of having a DLT by age strata and dose is presented. Estimation of MTD and/or recommended dose for expansion (RDE) at the dose-escalation phase of the study was based upon the estimation of the probability of DLT for participants in the dose-determining set (DDS).
- measure
- Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT
- time Frame
- Baseline, End of dose escalation phase (6 months)
- secondary Outcomes
- description
- The best overall clinical response was determined as per the clinical assessment done by the investigator. Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response. Participants with stable disease, progressive disease and with missing tumour assessment or who discontinued the study or who died before having their first assessment were considered as non-responders. Stable disease was defined as failure to achieve any of the above response. Progressive disease was defined as doubling of the bone marrow blast percentage from baseline in participants with \<40% bone marrow blasts at baseline, or a 50% increase in bone marrow blast percentage from baseline in participants with \>40% bone marrow blasts at baseline,
- measure
- Percentage of Participants With Best Overall Response by Indication
- time Frame
- Baseline, Day 15 (Day 1 of Cycle 2), Day 22 (Day 8 of Cycle 2), Day 29(Day 1 of Cycle 9), End of treatment (up to 24 months after last dose or until death whichever occurred first)
- description
- Time to response was defined as the time from the date of start of midostaurin treatment to the date of first response. The best overall clinical response was determined as per the clinical assessment done by the investigator. Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response. Time to response was calculated by using the formula = (date of first response -date of start of midostaurin) +1 day.
- measure
- Time to Response With Midostaurin
- time Frame
- Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
- description
- Overall survival (OS) was defined as the time from start of treatment to date of death due to any cause. The percentage (%) event-free probability estimates were obtained from the Kaplan-Meier survival estimates.
- measure
- Overall Survival With Midostaurin
- time Frame
- Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
- description
- The plasma concentrations of midostaurin (PKC412) and its two major metabolites, CGP62221 and CGP52421 were determined by using a validated liquid chromatography/tandem mass spectrometry method.
- measure
- Plasma Concentrations of Midostaurin and Its Metabolites CGP52421 and CGP62221
- time Frame
- Day 1, Day 5, Day 7, Day 15 (Day 1 of Cycle 2), Day 29 (Day 1 of Cycle 3)
- description
- An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs or SAEs were defined as AEs or SAEs that were suspected to be related to study treatment as per investigator. On treatment death was a fatal event leading to permanent cessations of all vital functions of the body.
- measure
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs or SAEs and Death During the Study
- time Frame
- Baseline (start of study treatment) up to End of treatment (up to 24 months after last dose or until death whichever occurred first)
Full study description
- brief Summary
- This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients \<18 years of age who have relapsed or refractory acute leukemias that may benefit from administration of midostaurin, including MLL-rearranged ALL and FLT3 positive AML.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-44c219d30a44ecbb5e15
- requested nct id
- NCT00866281
- primary nct id
- NCT00866281
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 90d0846124a802ccb9931af3b59ffc73885a89beb2d5c892861948391381f0f8
- payload
- application numbers
- NDA207997
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-44c219d30a44ecbb5e15
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00866281
- occurrences
- context exact
- open-label studies: a study in 22 pediatric patients aged 6 months to 17 years who received midostaurin as a single agent for relapsed or refractory leukemia [NCT00866281] and a study in 4 patients aged 8 to 14 years who received midostaurin in combination with chemotherapy for newly diagnosed FLT3-mutated AML [NCT03591510]. Pro
- end
- 387
- exact text
- NCT00866281
- start
- 376
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/32/pediatric_use/0
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- cb872639a3f179ec6b9860a082421eab5814b1133bb6ee0975f4ac6ffb7bb4d7
- spl effective time
- 20260608
- spl set id
- 11fa3fc9-6776-49a6-b1c1-653f627c3e58
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5a93efdc0adab6951d1f
- requested nct id
- NCT00866281
- primary nct id
- NCT00866281
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- cb72d92261f302444438657974874b1cb8bd0a2d8e781d1f0444eaf744cc9471
- payload
- application numbers
- NDA207997
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5a93efdc0adab6951d1f
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00866281
- occurrences
- context exact
- open-label studies: a study in 22 pediatric patients aged 6 months to 17 years who received midostaurin as a single agent for relapsed or refractory leukemia [NCT00866281] and a study in 4 patients aged 8 to 14 years who received midostaurin in combination with chemotherapy for newly diagnosed FLT3-mutated AML [NCT03591510]. Pro
- end
- 5167
- exact text
- NCT00866281
- start
- 5156
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/32/use_in_specific_populations/0
- source kind
- fda_spl_label
- source record id
- bc6574c1-6e9f-4aee-a755-517388595ef0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c529b0a33450424ec004df8250420b95cc0527247d875813fd4cab4822917f82
- spl effective time
- 20260608
- spl set id
- 11fa3fc9-6776-49a6-b1c1-653f627c3e58
Preserved source evidence · Not medical advice